The collaboration builds upon QIAGEN's acquisition of Cellestis Limited in August 2011 and the advanced QuantiFERON technology for highly sensitive, early detection of diseases. Cellestis already markets QuantiFERON-TB Gold, a leading test for detection of latent TB. Its pre-molecular technology identifies individuals at risk for life-threatening diseases by testing whole blood samples for the presence of systemically amplified molecular components, which provide information from the immune system's memory. QuantiFERON holds the potential to minimize outbreaks of active disease in early stages by identifying at-risk individuals and guiding the use of traditional DNA- and RNA-based molecular diagnostics for further profiling. This technology adds to QIAGEN's industry-leading portfolio of more than 120 assays for the diagnosis of various infectious diseases, including HIV, hepatitis and influenza, supported by instruments such as QIAsymphony RGQ, for efficient, automated laboratory workflows.
In the developed world, current screening protocols for TB typically identify individuals with positive test results (commonly up to 20% of high-risk patients screened) who need to be evaluated for active TB. A test combining TB infection markers with risk markers for the progression of latent into active TB could significantly increase the effectiveness of treatment options and disease control efforts. The market for latent TB testing is assumed to be approximately 50 million tests per year in the developed world.
"While the highest morbidity and mortality rates from TB disease occur in
|SOURCE QIAGEN N.V.|
Copyright©2010 PR Newswire.
All rights reserved